PMID- 27737598
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20181202
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 16
IP  - 1
DP  - 2017 Jan
TI  - The safety of anti PD-1 therapeutics for the treatment of melanoma.
PG  - 41-53
AB  - The introduction of immunotherapies into clinical practice has substantially 
      improved the prognosis of metastatic melanoma patients as well as patients 
      suffering from other cancers. The two FDA-approved checkpoint inhibitors against 
      PD-1 (nivolumab and pembrolizumab) have been shown to significantly improve 
      patient survival while being less toxic than previous treatment options. Areas 
      covered: The current scientific literature on safety and adverse events (AEs) 
      related to anti-PD-1 therapies has been investigated with special attention to 
      case reports and to the latest results announced at the major clinical cancer and 
      melanoma meetings, including ASCO (American Society of Clinical Oncology), ESMO 
      (European Society of medical Oncology) and EADO (European Association of 
      Dermato-Oncology) annual meetings. Expert opinion: Even though anti-PD-1 
      therapies are better tolerated than conventional chemo- or other 
      immune-therapies, they still induce a plethora of AEs. Given the mechanism of 
      action, it is supposed that most if not all of them are immune related. 
      Fortunately, the majority are mild and manageable. However, due to the increase 
      in patients' life expectancy, there is a substantial need to understand and 
      prevent severe cutaneous, pulmonary, neurological and other AEs which have major 
      impact on the quality of life. The safety profile after long term use of these 
      medications is still unclear. In addition, non-steroid based immune interventions 
      to control autoimmunity are still to be developed.
FAU - Ramelyte, Egle
AU  - Ramelyte E
AD  - a Department of Dermatology , University Hospital Zurich , Zurich , Switzerland.
AD  - b Centre of Dermatovenereology , Vilnius University Hospital Santariskiu klinikos 
      , Vilnius , Lithuania.
FAU - Schindler, Sabrina A
AU  - Schindler SA
AD  - a Department of Dermatology , University Hospital Zurich , Zurich , Switzerland.
FAU - Dummer, Reinhard
AU  - Dummer R
AD  - a Department of Dermatology , University Hospital Zurich , Zurich , Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161024
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (Nivolumab)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/administration & dosage/adverse effects/pharmacology
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/adverse 
      effects/pharmacology
MH  - Antineoplastic Agents/*administration & dosage/adverse effects/pharmacology
MH  - Humans
MH  - Immunotherapy/adverse effects/methods
MH  - Melanoma/*drug therapy/pathology
MH  - Nivolumab
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors
MH  - Quality of Life
MH  - Skin Neoplasms/*drug therapy/pathology
MH  - Survival
OTO - NOTNLM
OT  - Adverse events
OT  - anti-PD-1 antibody
OT  - immunotherapy
OT  - melanoma
EDAT- 2016/10/16 06:00
MHDA- 2017/03/11 06:00
CRDT- 2016/10/15 06:00
PHST- 2016/10/16 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
PHST- 2016/10/15 06:00 [entrez]
AID - 10.1080/14740338.2016.1248402 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2017 Jan;16(1):41-53. doi: 10.1080/14740338.2016.1248402. 
      Epub 2016 Oct 24.